Asuka Miyabashira - 18 Mar 2026 Form 3 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Role
President, Japan Pharma B.U.
Signature
/s/ Max Heuer, by power of attorney, for Asuka Miyabashira
Issuer symbol
TAK
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 06:16:15 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Miyabashira Asuka President, Japan Pharma B.U. 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, JAPAN /s/ Max Heuer, by power of attorney, for Asuka Miyabashira 18 Mar 2026 0002111457

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TAK Ordinary Shares 3,000 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 1,022 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 728 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 510 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,600 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (700 shares), June 1, 2027 (500 shares) and June 1, 2028 (400 shares).
F2 Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

Remarks:

Exhibit 24 Power of Attorney